Cargando…

Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver

BACKGROUND: Schisandrin B (Sch B) a main active component of Schisandra chinensis, has been shown to act as a liver protectant via activation of the Nrf2 pathway. Nevertheless, it remains unclear whether its reactive metabolite is responsible for Nrf2 activation; also, the effects of its reactive me...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shan, Qiu, Bingxun, Zou, Li, Liu, Ke, Xu, Xiaoyu, Zhu, Huifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267698/
https://www.ncbi.nlm.nih.gov/pubmed/30568426
http://dx.doi.org/10.2147/DDDT.S176561
_version_ 1783376134991249408
author Feng, Shan
Qiu, Bingxun
Zou, Li
Liu, Ke
Xu, Xiaoyu
Zhu, Huifeng
author_facet Feng, Shan
Qiu, Bingxun
Zou, Li
Liu, Ke
Xu, Xiaoyu
Zhu, Huifeng
author_sort Feng, Shan
collection PubMed
description BACKGROUND: Schisandrin B (Sch B) a main active component of Schisandra chinensis, has been shown to act as a liver protectant via activation of the Nrf2 pathway. Nevertheless, it remains unclear whether its reactive metabolite is responsible for Nrf2 activation; also, the effects of its reactive metabolite on liver function are still unknown. METHODS: The present study determined and identifed the carbene reactive metabolite of Sch B in human and mice liver microsomes. Its roles in activating Nrf2 pathway and modifying macromolecules were further explored in human liver microsomes. Moreover the potential cytotoxicity and hepatoxicity of carbene on HepG-2 and mice were also investigated. RESULTS: In the present study, cytochromes P450 (CYP450s) metabolized Sch B to carbene reactive metabolite, which, with the potential to modify peptides, were identifed and observed in human and mice liver microsomes. Moreover, the relevance of carbene in Nrf2 activation was verifed by co-incubation in the presence of CYP450 inhibitors in HepG-2 cells, as well as by molecular docking study of carbene and Keap1. Additionally, the cytotoxicity of Sch B on HepG-2 cells was signifcantly aggravated by CYP450 inducer (with LD(50) decreasing from 63 to 21 µM) and signifcantly alleviated by CYP450 inhibitor and glutathione (with LD(50) increasing from 63 µM to 200 µM). Besides, after oral administration of mice with Sch B (25–100 mg/kg) for 21 days, only the highest dose induced mild hepatotoxicity, which was accompanied by increasing the aminotransferase activity and centrilobular hepatocellular infltration of lymphocytes. In addition, upregulation of CYP450 activity; Nrf2, NQO-1, and GST expression; and glutathione level was observed in Sch B treatment groups. CONCLUSION: The present study revealed that CYP450s mediate the conversion of Sch B to carbene, which subsequently binds to Keap1 and elicits Nrf2 pathway, which could further increase the elimination of carbene and thus exhibit a less harmful effect on mice liver.
format Online
Article
Text
id pubmed-6267698
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62676982018-12-19 Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver Feng, Shan Qiu, Bingxun Zou, Li Liu, Ke Xu, Xiaoyu Zhu, Huifeng Drug Des Devel Ther Original Research BACKGROUND: Schisandrin B (Sch B) a main active component of Schisandra chinensis, has been shown to act as a liver protectant via activation of the Nrf2 pathway. Nevertheless, it remains unclear whether its reactive metabolite is responsible for Nrf2 activation; also, the effects of its reactive metabolite on liver function are still unknown. METHODS: The present study determined and identifed the carbene reactive metabolite of Sch B in human and mice liver microsomes. Its roles in activating Nrf2 pathway and modifying macromolecules were further explored in human liver microsomes. Moreover the potential cytotoxicity and hepatoxicity of carbene on HepG-2 and mice were also investigated. RESULTS: In the present study, cytochromes P450 (CYP450s) metabolized Sch B to carbene reactive metabolite, which, with the potential to modify peptides, were identifed and observed in human and mice liver microsomes. Moreover, the relevance of carbene in Nrf2 activation was verifed by co-incubation in the presence of CYP450 inhibitors in HepG-2 cells, as well as by molecular docking study of carbene and Keap1. Additionally, the cytotoxicity of Sch B on HepG-2 cells was signifcantly aggravated by CYP450 inducer (with LD(50) decreasing from 63 to 21 µM) and signifcantly alleviated by CYP450 inhibitor and glutathione (with LD(50) increasing from 63 µM to 200 µM). Besides, after oral administration of mice with Sch B (25–100 mg/kg) for 21 days, only the highest dose induced mild hepatotoxicity, which was accompanied by increasing the aminotransferase activity and centrilobular hepatocellular infltration of lymphocytes. In addition, upregulation of CYP450 activity; Nrf2, NQO-1, and GST expression; and glutathione level was observed in Sch B treatment groups. CONCLUSION: The present study revealed that CYP450s mediate the conversion of Sch B to carbene, which subsequently binds to Keap1 and elicits Nrf2 pathway, which could further increase the elimination of carbene and thus exhibit a less harmful effect on mice liver. Dove Medical Press 2018-11-23 /pmc/articles/PMC6267698/ /pubmed/30568426 http://dx.doi.org/10.2147/DDDT.S176561 Text en © 2018 Feng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Feng, Shan
Qiu, Bingxun
Zou, Li
Liu, Ke
Xu, Xiaoyu
Zhu, Huifeng
Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title_full Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title_fullStr Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title_full_unstemmed Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title_short Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
title_sort schisandrin b elicits the keap1-nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267698/
https://www.ncbi.nlm.nih.gov/pubmed/30568426
http://dx.doi.org/10.2147/DDDT.S176561
work_keys_str_mv AT fengshan schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver
AT qiubingxun schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver
AT zouli schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver
AT liuke schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver
AT xuxiaoyu schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver
AT zhuhuifeng schisandrinbelicitsthekeap1nrf2defensesystemviacarbenereactivemetabolitewhichislessharmfultomiceliver